前立腺肥大症に伴う排尿障害に対する塩酸タムスロシンの臨床評価 : 尿道内圧曲線及び膀胱内圧曲線に対する効果

Abstract

前立腺肥大症に伴う排尿障害患者に対して塩酸タムスロシン0.2mg/日を7週間投与して, その臨床的有用性を検討した. 1)自覚症状スコアは有意に改善した. 2)残尿量及び残尿率は有意に減少した. 3)尿流検査で排尿量, 最大尿流率及び平均尿流率は有意に増加した. 4)尿道内圧曲線で前立腺部尿道内圧は有意に低下した. 5)膀胱内圧曲線で初発尿意時膀胱容量は有意に増加した. 6)副作用は3例の軽度検査値上昇以外は認められなかった

The efficacy and safety of tamsulosin hydrochloride were evaluated in 54 patients with bladder outlet obstruction associated with benign prostatic hyperplasia. Oral tamsulosin hydrochloride 0.2 mg was administered once daily for 7 weeks. The international prostate symptom score, residual urine, uroflowmetrogram, urethral pressure profile and cystometrogram were obtained before and after treatment. The international prostate symptom score improved significantly, and the residual urine volume and ratio of residual urine decreased significantly. In uroflometry, voided volume, maximum flow rate and average flow rate increased significantly. In urethral pressure profile, prostatic urethral pressure decreased significantly. In cystometry, bladder capacity at the first sensation increased significantly. No adverse reactions except for slight elevation in laboratory data in 3 patients were observed. In conclusion, tamsulosin hydrochloride is a useful drug in the treatment of bladder outlet obstruction associated with benign prostatic hyperplasia.